A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1

Rieko Nakamura, Yoshiro Saikawa, Koushi Kumagai, Tsuyoshi Kiyota, Masaki Ohashi, Masashi Yoshida, Tetsuro Kubota, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+α lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.

Original languageEnglish
Pages (from-to)295-299
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - 2007 Aug

Fingerprint

Liver Neoplasms
Combination Drug Therapy
Stomach Neoplasms
Neoplasm Metastasis
Liver
irinotecan
docetaxel
Drug Therapy
Tomography
Gastrectomy
Lymph Node Excision
Informed Consent
Cisplatin
Stomach
Outpatients
Radiotherapy
Neoplasms
Therapeutics

Keywords

  • Combination chemotherapy
  • Gastric cancer
  • Liver metastases
  • S-1

ASJC Scopus subject areas

  • Oncology

Cite this

A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. / Nakamura, Rieko; Saikawa, Yoshiro; Kumagai, Koushi; Kiyota, Tsuyoshi; Ohashi, Masaki; Yoshida, Masashi; Kubota, Tetsuro; Kumai, Koichiro; Kitajima, Masaki.

In: International Journal of Clinical Oncology, Vol. 12, No. 4, 08.2007, p. 295-299.

Research output: Contribution to journalArticle

Nakamura, Rieko ; Saikawa, Yoshiro ; Kumagai, Koushi ; Kiyota, Tsuyoshi ; Ohashi, Masaki ; Yoshida, Masashi ; Kubota, Tetsuro ; Kumai, Koichiro ; Kitajima, Masaki. / A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. In: International Journal of Clinical Oncology. 2007 ; Vol. 12, No. 4. pp. 295-299.
@article{995b16864d7c44d88eeb96a53d4844b2,
title = "A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1",
abstract = "We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+α lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.",
keywords = "Combination chemotherapy, Gastric cancer, Liver metastases, S-1",
author = "Rieko Nakamura and Yoshiro Saikawa and Koushi Kumagai and Tsuyoshi Kiyota and Masaki Ohashi and Masashi Yoshida and Tetsuro Kubota and Koichiro Kumai and Masaki Kitajima",
year = "2007",
month = "8",
doi = "10.1007/s10147-006-0648-4",
language = "English",
volume = "12",
pages = "295--299",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1

AU - Nakamura, Rieko

AU - Saikawa, Yoshiro

AU - Kumagai, Koushi

AU - Kiyota, Tsuyoshi

AU - Ohashi, Masaki

AU - Yoshida, Masashi

AU - Kubota, Tetsuro

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2007/8

Y1 - 2007/8

N2 - We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+α lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.

AB - We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+α lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.

KW - Combination chemotherapy

KW - Gastric cancer

KW - Liver metastases

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=34547860895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547860895&partnerID=8YFLogxK

U2 - 10.1007/s10147-006-0648-4

DO - 10.1007/s10147-006-0648-4

M3 - Article

VL - 12

SP - 295

EP - 299

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -